DNA
BRAF | ERCC2 | FGFR1 | FGFR2 | FGFR3 | MTOR | NTRK1 | NTRK3 | SMAD4 | FBXW7 | TP53 |
FUSION
FGFR2 Fusion | FGFR3 Fusion | NTRK1 Fusion | NTRK2 Fusion | NTRK3 Fusion | RET Fusion | MET Fusion | PD-L1 IHC | Microsatellite Instability (MSI) |
Method: Next Generation Sequencing (NGS)
Sample Type: Tissue, Blood (Liquid Biopsy Tube)
Result Time: 20-25 Days
Sensitivity: 99%
Description: 11 Gen - 7 Fusion + MSI + PD-L1 IHC
BLADDER PLUS PANEL
✓ Paraffin Block ✓ Liquid Biopsy
BLADDER PLUS PANEL
Bladder cancer has recently become one of the cancer types with significant advances in studies with newly developed drugs. Comprehensive genetic analysis, especially FGFR fusion, is recommended for eligibility for smart therapies after first-line treatment. In addition, PDL1 analysis can be very guiding in determining the decision of Adjuvant Immunotherapy in early stage bladder cancer.